Актуальность. Адипонектин (АН) - протективный адипоцитокин, продуцируемый жировой тканью и циркулирующий в крови в виде различных изомеров. При абдоминальном ожирении (АО) сниженная концентрация АН ассоциируется с развитием метаболи- ческого синдрома (МС), его отдельных компонентов и различных сердечно-сосудистых заболеваний. АН кодируется геном ADIPOQ . Показано, что генетические варианты ADIPOQ ассоциированы с изменением концентрации АН сыворотки крови.Цель исследования. Выявить ассоциации полиморфных вариантов T(+45)G rs2441766 и С(-11377)G rs 266729 гена ADIPOQ с кон- центрацией АН сыворотки крови, АО и МС у женщин.Результаты. Обследованы 302 женщины с АО в возрасте от 30 до 55 лет. Группу сравнения составила 161 практически здоровая женщина без АО. У 185 обследованных с АО был диагностирован МС в соответствии с критериями Международной федерации диа- бета (IDF, 2005). Частоты генотипов и аллелей вариантов T(+45)G и С(-11377)G гена ADIPOQ у женщин с АО и без АО не различались (р>0,05). Среди женщин с АО и МС реже встречались носители аллеля G варианта T(+45)G гена ADIPOQ , чем среди женщин с АО без МС (р<0,05). Частоты генотипов и аллелей варианта С(-11377)G гена ADIPOQ у женщин с АО и МС и у пациенток с АО без МС не разли- чались (р>0,05). У женщин с АО - носителей аллеля G варианта T(+45)G гена ADIPOQ концентрация высокомолекулярного АН (ВМАН) была выше, чем у носителей генотипа TТ этого гена. При анализе частот гаплотипов вариантов T(+45)G и С(-11377)G гена ADIPOQ в обследованных группах достоверных различий не выявлено (р>0,05). Концентрации общего АН в сыворотке крови у женщин с АО и МС - носителей различных генотипов и гаплотипов вариантов T(+45)G и С(-11377)G гена ADIPOQ не различались (р>0,05). Концен- трация ВМАН у женщин с АО - носителей гаплотипа TGC(X) (Х - аллель С или G варианта С(-11377)G ) была выше, чем у женщин с АО - носителей других гаплотипов гена ADIPOQ (р<0,05).Выводы. Носительство аллеля G варианта T(+45)G гена ADIPOQ является протективным в отношении МС у женщин с АО. У женщин с АО - носителей аллеля G концентрация ВМАН выше, чем у женщин с АО - носителей TT генотипа варианта T(+45)G гена ADIPOQ . Background. Adiponectin (AN) - a protective adipocytokine, produced by fat tissue and circulating in the form of various isomers in the blood. With obesity, a decreased level of AN is associated with the development of metabolic syndrome (MS) and various cardiovascular diseases. Regulation of its level can be caused by genetic factors, including single nucleotide polymorphism T(+45)G and C(-11377)G of the ADIPOQ gene. Allelic variants of the ADIPOQ gene was associated with AN concentrarion in blood.Objective. To identify the association of genetic variants of ADIPOQ with adiponectin level, AO and MS in women.Results. A total of 302 women with abdominal obesity (AO) aged 30-55 years were examined. The comparison group consisted of 161 practically healthy women without AO. 185 patients with AO had MS according to the criteria of the International Diabetes Federation (IDF, 2005). The frequencies of genotypes and alleles of variants T (+45) G and C (-11377) G of the ADIPOQ gene among women with and without AO did not differ (p> 0,05). Among women with AO and MS, carriers of G allele variant T (+45) G of the ADIPOQ gene were less common than among women with AO without MS (р<0,05). The frequencies of genotypes and alleles of variant C (-11377) G of the ADIPOQ gene did not differ in women with AO and MS and in patients with AO without MS (p> 0.05). In women with AO - carriers of the G allele variant T (+45) G of the ADIPOQ gene, the concentration of high molecular weight AN (HMWA) was higher than that of the TT carriers of the genotype of this gene The haplotypes of the T (+45) G and C (-11377) G variants of the ADIPOQ gene did not differ in the studied groups (p> 0,05). The con- centration of total AN in the serum of women with AO and MS - carriers of different genotypes and haplotypes of variants T (+45) G and C (-11377) G of the ADIPOQ gene did not differ (p> 0,05). The concentration of HMWA in women with AO - carriers of the TGC(X) haplotype (X - allele C or G variant C (-11377) G) was higher than in women with AO - carriers of other haplotypes of the ADIPOQ gene (p <0,05). Coclusions. G allele of the T(+45)G variant the ADIPOQ gene is protective against MS in women with AO. In women with AO - carriers of the G allele, the concentration of HMWA is higher than in women with AO - carriers of the TT genotype of variant T(+45)G of the ADIPOQ gene.
Objective. To assess the expression of the leptin gene (LEP) in the epicardial (EAT) and subcutaneous (SAT) adipose tissue in coronary artery disease (CAD) patients.Methods. 107 people were examined: 87 with CAD (57 men, 30 women), 20 without CAD (10 men, 10 women). Biopsy of EAT, SAT, coronary angiography, heart computed tomography, blood leptin levels were estimate, mRNA expression of the LEP gene evaluated by PCR.Results. In CAD patients with multivessel coronary artery lesion, the level of blood leptin is the highest. The expression of the LEP gene in EAT is higher in men than in women, in men with CAD higher than in non-coronary artery disease patients, and with a multivascular coronary lesion higher than in a 1–2 vascular lesion. Expression of the LEP gene in EAT in women with CAD is higher than with no CAD, and does not depend on the severity of coronary atherosclerosis. In SAT, LEP gene expression in men with CAD is higher than without CAD; women with CAD are lower than without CAD. Expression of the LEP gene in SAT is higher in men with a multivascular lesion than in 1–2 vascular lesion, and lower in women with a multivascular damage.Conclusions. The expression of the leptin gene in women is higher in SAT, and in men in EAT. Expression of the leptin gene in EAT with CAD is higher than without CAD. The expression of the leptin gene in SAT in men with CAD, especially with multivessel lesions, is higher than without coronary artery disease.
Background. Omentin-1 (QM-1) — one of the most important anti-inflammatory adipocytokines produced by adipose tissue. It is known that its concentration is reduced in obese patients. However, the role of OM-\ in the pathogenesis of coronary heart disease (CHD), including acute coronary syndrome (ACS), is not fully determined.The objective of the study — to assess the level of OM-1 in blood serum of patients with ACS without ST-segment elevation (ACSWEST) who underwent percutaneous coronary intervention (PCI) and patients with stable CHD.Design and methods. Examined 104 patients with ACSWEST undergoing PCI. Comparison groups consisted of 38 patients without CHD according negative results of stress-echocardiography or coronary angiography, as well as 80 patients with stable CHD. All patients were evaluated anthropometric indicators: height, weight, waist circumference (WC), body mass index (BMI). Serum concentrations of OM-I were determined by enzyme immunoassay (DRG,USA), serum lipid profile was determined by enzymatic method.Results. In patients with ACSWEST who underwent PCI, the concentration of OM-I in the blood is lower than in those examined without atherosclerotic lesions of the coronary arteries [7.53 (5.00-10.55) ng/ml and 12.56 (7.84-15.34) ng/ml, respectively; p < 0.001). The concentration of OM-1 in the blood in patients with ACSWEST and a stable CHD did not differ (p > 0.05). In patients with ACSWEST, the concentration of OM-1 blood with multivascular lesions of the coronary arteries is lower than with 1-2 vascular lesions [7.30 (3.91- 8.17) ng/ml and 9.44 (6.54-9.93) ng/ml, respectively; p < 0.001. Similar patterns were established in patients with a stable CHD (p < 0.001).The concentration of OM-1 inthe blood in women with ACSWEST, with stable CHD and in those examined without CHD was higher than in men of the corresponding groups (p < 0.001).In patients with ACSWEST and with a stable CHD with overweight and obesity (WHO, 1999), the concentration of OM-1 inblood serum is lower than in patients with CHD and normal BMI (p < 0.001). In patients with ACSWEST and AO, the level of OM-1 inthe blood is lower than in patients with ACSWEST without AO, both in men and women (p < 0.001). When conducting a regression analysis, it was found that the concentration of OM-1 inthe blood of patients with ACSWEST is determined by BMI (b = -0.30, beta = -0.23, p = 0.002) and patient gender (b = 2.21, beta = 0.16, p = 0.029); in patients with a stable CHD — BMI (b = -0.38, beta = -0.27, p = 0.029).Conclusion. For patients with CHD, both with ACSWEST and with stable CHD, a low level of OM-1 in the blood is characteristic. The lowest OM-1 values were found in patients with multivascular coronary artery disease and obesity. The gender characteristics of the concentration of OM-1 in serum were established: the concentration of OM-1 in serum in women is higher than in men. A decrease in the concentration of OM-1 in the blood in patients with ACSWEST and with stable CHD is associated with BMI, the patient’s gender, and the severity of coronary atherosclerosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.